AGEN

AGEN

USD

Agenus Inc. Common Stock

$3.980+0.140 (3.646%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$3.840

Máximo

$3.980

Mínimo

$3.700

Volumen

0.33M

Fundamentos de la Empresa

Capitalización de Mercado

126.8M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.46M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $1.38Actual $3.980Máximo $7.34

Noticias Relacionadas

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $23 price target.

Ver más
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
BusinessWire

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable

Ver más
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
Earnings Call Transcripts

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Ver más
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
PR Newswire

FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with...

Ver más
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $23 price target.

Ver más
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
BusinessWire

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Webcast details updated from the August 11th release Webcast on Wednesday, August 27, 2025 at 4:00 p.m. EST Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.